Elizabeth Olson Hexner

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service
Assistant Director, MTR program, Perelman School of Medicine
Medical Director, Center for Cellular Immunotherapies, Perelman School of Medicine
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-106
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-6348
Fax: 215-615-5888
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Permanent link

Description of Research Expertise

Myeloproliferative Disorders
Umbilical Cord Blood Transplantation

Description of Itmat Expertise

Dr. Hexner conducts translational research in experimental transplantation and preclinical early phase studies pertaining to new therapies for myeloproliferative diseases.

Selected Publications

Meng, L., Bai, Z., He, S., Mochizuki, K., Liu, Y., Purushe, J., Sun, H., Wang, J., Yagita, H., Mineishi, S., Fung, H., Yanik, G. A., Caricchio, R., Fan, X., Crisalli, L. M., Hexner, E. O., Reshef, R., Zhang, Y., Zhang, Y.: The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol 196(3): 1070-80, Feb 1 2016.

Hexner, E. O., Luger, S. M., Reshef, R., Jeschke, G. R., Mangan, J. K., Frey, N. V., Frank, D. M., Richman, L. P., Vonderheide, R. H., Aqui, N. A., Rosenbach, M., Zhang, Y., Chew, A., Loren, A. W., Stadtmauer, E. A., Levine, B. L., June, C. H., Emerson, S. G., Porter, D. L.: Infusion of CD3/CD28 co-stimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol 2016.

Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., Villeneuve, M., Huntsman Labed, A., Stanek, E. J., Hartmann, K., Horny, H. P., Valent, P., Reiter, A.: Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med 374(26): 2530-41, 2016.

Yam, C., Crisalli, L., Luger, S. M., Loren, A. W., Hexner, E. O., Frey, N. V., Mangan, J. K., Gao, A., Stadtmauer, E. A., Porter, D. L., Reshef, R.: Unrelated donors are associated with improved relapse free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem-cell transplantation. Am J Hematol 2016.

Kumar, A. J., Vassilev, P., Loren, A. W., Luger, S. M., Reshef, R., Gill, S., Smith, J., Goldstein, S. C., Hexner, E., Stadtmauer, E. A., Porter, D., Frey, N. V.: Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. Am J Hematol 91(4): 426-9, 2016.

Ganetsky, A., Shah, A., Miano, T. A., Hwang, W. T., He, J., Loren, A. W., Hexner, E. O., Frey, N. V., Porter, D. L., Reshef, R.: Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant Dec 2015 Notes: Epub ahead of print.

Orlowski R, Huang A, Gohil M, Mangan J, Vignali M, Emerson R, Robins H, Yusko E, Jordan M, Carroll M, Gilliland DG, Hexner E: Integrated Immunological Analysis of the Bone Marrow Tumor Microenvironment in Myeloproliferative Neoplasms to Determine Potential Efficacy of Immune Checkpoint Blockade. Blood 126(2766), December 2015.

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Raza, A., Vaddi, K., Sun, W., Peng, W., Sandor, V., Kantarjian, H.: Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 100(9): 1139-45, Sep 2015.

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 100(4): 479-88, Apr 2015.

Reilly CR, Babushok D, Bahirwani R, Mondschein J, Hexner E: Clinical Characteristics and Outcomes of Transjugular Intrahepatic Portosystemic Shunt Procedure for Portal Hypertension Secondary to Myeloproliferative Neoplasms. Blood 126(1612), 2015.

back to top
Last updated: 08/01/2016
The Trustees of the University of Pennsylvania